Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224198 | 0.89 | MAPT (0.61) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL5225221 | 0.87 | MAPT (0.65) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL5218874 | 0.86 | TP53 (0.77) | MAPTRXFP1THRBTP53CCNT1 | |
| SCHEMBL5219688 | 0.83 | MAPT (0.69) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL5784401 | 0.83 | MAPT (0.59) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL5221497 | 0.81 | TP53 (0.50) | MAPTRXFP1THRBTP53CCNT1 | |
| SCHEMBL5047363 | 0.81 | MAPT (0.69) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL5220994 | 0.81 | MAPT (0.76) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL6489253 | 0.81 | MAPT (0.83) | MAPTRXFP1THRBTP53ADRB2 | |
| SCHEMBL6480075 | 0.80 | TDP1 (0.53) | MAPTRXFP1THRBPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618094-A1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-01-25 | — | — | EP | claimed |
| US-20050009817-A1 | Substituted heteroaryls | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-13 | — | — | US | claimed |
| WO-2004099159-A1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1618094-B1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INST FOR PHARM DISCOVERY INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1618094-B1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INST FOR PHARM DISCOVERY INC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20050009817-A1 | Substituted heteroaryls | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009817-A1 | Substituted heteroaryls | PTPRS, PTPRO, PTPRR | MAPT 1878/4885RXFP1 4220/4885THRB 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.